 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || WU CART 007 / Wugen
P1/2 data, Journal: Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. (Pubmed Central) - Aug 16, 2024
P1/2
WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
- |||| WU CART 007 / Wugen
New P2 trial, CAR T-Cell Therapy, Minimal residual disease: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - Jul 22, 2024
P2, N=125, Not yet recruiting, Sponsor: Wugen, Inc.
- WU CART 007 / Wugen
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) (Stars at Night B1 (Ballroom Level, Henry B. Gonzalez Convention Center); in-person) - Dec 5, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_654;
P1/2
WU-CART-007 has demonstrated an acceptable safety profile and preliminary evidence of anti-leukemic activity. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL.
- | WU CART 007 / Wugen
Enrollment closed: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov) - Nov 27, 2023
P1/2, N=44, Active, not recruiting, Sponsor: Wugen, Inc.
This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL. Recruiting --> Active, not recruiting
- WU CART 007 / Wugen
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T... (SDCC - Room 6CF) - Nov 3, 2023 - Abstract #ASH2023ASH_4897;
P1/2
Two different LDC regimens have been tested: standard LDC (fludarabine 30 mg/m 2 /day x 3 days and cyclophosphamide 500 mg/m 2 /day x 3 days), and enhanced LDC (eLDC; fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...Most (72%; 13/18) pts had G1-2 CRS events; a single G3 CRS event was reported which resolved within 72 hours after receiving tocilizumab, dexamethasone, and low-dose vasopressors...This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL. Enrollment is ongoing.
- ||| WU CART 007 / Wugen
Enrollment open, CAR T-Cell Therapy: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - Oct 12, 2023
P1, N=54, Recruiting, Sponsor: Washington University School of Medicine
Enrollment is ongoing. Not yet recruiting --> Recruiting
- WU CART 007 / Wugen, Actemra IV (tocilizumab) / Roche, JW Pharma
PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL) (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1485;
P1/2
in a subset of patients. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL.
- || WU CART 007 / Wugen
Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - May 9, 2023
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL. Trial completion date: Sep 2025 --> Jan 2026 | Initiation date: Mar 2023 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jan 2026
- || WU CART 007 / Wugen
Trial initiation date, CAR T-Cell Therapy: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 (clinicaltrials.gov) - Mar 8, 2023
P=N/A, N=44, Enrolling by invitation, Sponsor: Wugen, Inc.
Trial completion date: Sep 2025 --> Jan 2026 | Initiation date: Mar 2023 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jan 2026 Initiation date: Dec 2022 --> Aug 2022
- || WU CART 007 / Wugen
Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - Jan 18, 2023
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
Initiation date: Dec 2022 --> Aug 2022 Trial completion date: Jun 2025 --> Sep 2025 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2025 --> Sep 2025
- || WU CART 007 / Wugen
Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - Sep 29, 2022
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jun 2025 --> Sep 2025 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2025 --> Sep 2025 Trial completion date: Feb 2025 --> Jun 2025 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Feb 2025 --> Jun 2025
- || WU CART 007 / Wugen
Trial initiation date, CAR T-Cell Therapy: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 (clinicaltrials.gov) - Sep 2, 2022
P=N/A, N=44, Enrolling by invitation, Sponsor: Wugen, Inc.
Trial completion date: Feb 2025 --> Jun 2025 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Feb 2025 --> Jun 2025 Initiation date: Aug 2022 --> Dec 2022
- |||||| WU CART 007 / Wugen
New trial, CAR T-Cell Therapy: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 (clinicaltrials.gov) - Aug 22, 2022
P=N/A, N=44, Enrolling by invitation, Sponsor: Wugen, Inc.
- || WU CART 007 / Wugen
New P1 trial, CAR T-Cell Therapy: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov) - May 16, 2022
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| WU CART 007 / Wugen
CAR T-Cell Therapy: Finally, fratricide-resistant CD7+ CART study WU-CART-007 open and enrolling for T-cell ALL @WUSTLmed @SitemanCenter bringing a new immunotherapeutic option for T cell malignancies, work by our leader @DiPersioLab #leusm #CARTcell (Twitter) - Feb 10, 2022
- || WU CART 007 / Wugen
Enrollment open, CAR T-Cell Therapy: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov) - Feb 1, 2022
P1/2, N=44, Recruiting, Sponsor: Wugen, Inc.
Initiation date: Aug 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- WU CART 007 / Wugen
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) () - Nov 24, 2021 - Abstract #ASH2021ASH_6566;
Response will be assessed on Cycle 1 Day 28 (± 1 days), and at Months 3, 6, 12, and 24, by bone marrow aspirate and biopsy and PET/CT if indicated. Response will be defined as per modified NCCN Guidelines Version 2.2020.
- WU CART 007 / Wugen
Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4416;
Conclusions These preclinical studies support the use of WU-CART-007 in clinical trials and highlight the potential of WU-CART-007 to be a well-tolerated and active therapy for patients with CD7+ T-cell malignancies. A first in human Phase 1/2 trial in patients with R/R T-ALL/LBL is currently open for enrollment (NCT# 04984356).
- || WU CART 007 / Wugen
New P1/2 trial, CAR T-Cell Therapy: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov) - Jul 30, 2021
P1/2, N=44, Not yet recruiting, Sponsor: Wugen, Inc.